delicious
Digg
Facebook
LinkedIn
Mixx
Twitter
Yahoo! Buzz
HORSHAM, PA, July 21, 2011 - Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy. REMICADE® was designated orphan drug status by the FDA on November 12, 2003 for the treatment of pediatric UC, and the supplemental Biologics License Application (sBLA) received priority review following its submission to the FDA in December 2010.
REMICADE®, an anti-tumor necrosis factor (TNF)-alpha therapy, is currently approved for the treatment of adults with moderately to severely active UC, and adults and children with moderately to severely active Crohn's disease. In addition, REMICADE® is approved for the treatment of moderately to severely active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and chronic, severe plaque psoriasis.
"We are pleased with the advisory committee's support for the approval of REMICADE® as a treatment for pediatric ulcerative colitis," said Jerome A. Boscia, M.D., Vice President, Head of Immunology Development, Centocor Research & Development division of Johnson & Johnson Pharmaceutical Research & Development, L.L.C. "We hope the FDA will consider this recommendation and approve REMICADE® for this orphan disease."
The committee reviewed data from a Phase 3 randomized, multicenter, open-label trial evaluating the efficacy and safety of REMICADE® in the treatment of pediatric patients with moderately to severely active UC and voted the benefit:risk profile supports the approval of REMICADE® for pediatric UC indications including induction and maintenance of clinical remission and induction of mucosal healing.
However, the committee did not recommend REMICADE for pediatric UC indications of maintenance of mucosal healing and eliminating corticosteroid use. Results from the trial were presented in May and showed that treatment with REMICADE® 5 mg/kg induced clinical response in 73 percent of patients at week 8 and demonstrated a safety profile consistent with previous clinical trials conducted in an adult population.
GIDAC is convened upon request of the FDA to review and evaluate safety and efficacy data of human drug products for use in the treatment of gastrointestinal diseases. The committee provides non-binding recommendations based on its evaluation; the FDA is not bound by the committee's recommendation, but does take its advice into consideration.
About Ulcerative Colitis
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) of the colon. It is estimated that 1.4 million Americans have IBD with the number evenly split between UC and Crohn's disease. An estimated 150,000 children under age 17 are living with debilitating symptoms of IBD.1
About REMICADE®
REMICADE® was the first anti-tumor necrosis factor (TNF)-alpha treatment approved in the United States in August 1998 and the first TNF inhibitor to be approved in three different therapeutic areas: gastroenterology, rheumatology and dermatology. REMICADE® has demonstrated broad clinical utility with indications in Crohn's disease, rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic arthritis, ulcerative colitis (UC), pediatric Crohn's disease and psoriasis. The safety and efficacy of REMICADE® have been well established in clinical trials over the past 17 years and through commercial experience with more than 1.5 million patients treated worldwide.
In the U.S., REMICADE® is approved for the following indications:
REMICADE® is unique among available anti-TNF-alpha biologic therapies. It is the only anti-TNF-alpha biologic administered directly by caregivers in the clinic or office setting. REMICADE® is a two-hour infusion administered every 6 or 8 weeks (indication-dependent), following a standard induction regimen that requires treatment at weeks 0, 2 and 6. As a result, REMICADE® patients may require as few as six treatments each year as maintenance therapy.
Janssen Biotech, Inc. discovered and developed REMICADE® and markets the product in the United States. The Janssen Pharmaceutical Companies market REMICADE® in Canada, Central and South America, the Middle East, Africa and Asia Pacific.
In Japan, Indonesia, and Taiwan, Janssen Biotech, Inc. licenses distribution rights to REMICADE® to Mitsubishi Tanabe Pharma Corporation. In Europe, Russia and Turkey, Janssen Biotech, Inc. licenses distribution rights to REMICADE® to Schering-Plough (Ireland) Company, a subsidiary of Merck & Co, Inc.
Important Safety Information
Only a doctor can recommend a course of treatment after checking a patient's health condition. REMICADE® (infliximab) can cause serious side effects such as lowering your ability to fight infections. There are reports of serious infections caused by viruses, fungi or bacteria that have spread throughout the body, including tuberculosis (TB) and histoplasmosis. Some of these infections have been fatal. Your doctor should monitor you closely for signs and symptoms of TB during treatment with REMICADE®.
Unusual cancers have been reported in children and teenage patients taking TNF-blocker medicines. A rare form of fatal lymphoma has occurred mostly in teenage or young adult males with Crohn's disease or ulcerative colitis who were taking REMICADE® and azathioprine or 6-mercaptopurine. For children and adults taking TNF blockers, including REMICADE®, the chances of getting lymphoma or other cancers may increase.
Patients should discuss any concerns about their health and medical care with their doctor.
Patients should let their doctors know if they have or ever had any of the following:
The following serious (sometimes fatal) side effects have been reported in people taking REMICADE®. Patients should tell their doctors right away if you have any of the signs listed below:
Please read important information about REMICADE®, including full U.S. prescribing information and Medication Guide, at www.remicade.com.
About Janssen Biotech, Inc.
Janssen Biotech, Inc. redefines the standard of care in immunology, oncology, urology and nephrology. Built upon a rich legacy of innovative firsts, Janssen Biotech, Inc. has delivered on the promise of new treatments and ways to improve the health of individuals with serious disease. Beyond its innovative medicines, Janssen Biotech, Inc. is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates, and health care professionals have access to the latest treatment information, support services, and quality care. Janssen Biotech, Inc. is one of the Janssen Pharmaceutical Companies which are dedicated to addressing and solving some of the most important unmet medical needs in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we work together to bring innovative ideas, products, services and solutions to people throughout the world.
For more information on Janssen Biotech, Inc. or its products, visit www.janssenbiotech.com or follow us on Twitter at www.twitter.com/JanssenUS.
References:
1. Crohn's & Colitis Foundation of America and the Starlight Children's Foundation. Give me some numbers! What are the most current IBD-related statistics? Available at: http://www.ucandcrohns.org/src_subarticle.php?c=&id=2&page=3&tbl=src_faq. Accessed June 15, 2011.